653
Views
44
CrossRef citations to date
0
Altmetric
Original Research

The influence of time horizon on results of cost-effectiveness analyses

ORCID Icon, , , , &
Pages 615-623 | Received 16 Mar 2017, Accepted 14 May 2017, Published online: 23 May 2017
 

ABSTRACT

Background: Debates persist on the appropriate time horizon from a payer’s perspective and how the time horizon in cost-effectiveness analysis (CEA) influences the value assessment.

Methods: We systematically reviewed the Tufts Medical Center CEA Registry and identified

US-based studies that used a payer perspective from 2005–2014. We classified the identified CEAs as short-term (time horizon ≤ 5 years) and long-term (> 5 years), and examined associations between study characteristics and the specified time horizon. We also developed case studies with selected interventions to further explore the relationship between time horizon and projected costs, benefits, and incremental cost-effectiveness ratios (ICER).

Results: Among 782 identified studies that met our inclusion criteria, 552 studies (71%) utilized a long-term time horizon while 198 studies (25%) used a short-term horizon. Among studies that employed multiple time horizons, the extension of the time horizon yielded more favorable ICERs in 19 cases and less favorable ICERs in 4 cases. Case studies showed the use of a longer time horizon also yielded more favorable ICERs.

Conclusion: The assumed time horizon in CEAs can substantially influence the value assessment of medical interventions. To capture all consequences, we encourage the use of time horizons that extend sufficiently into the future.

Acknowledgements

Researchers at Tufts Medical Center retained full control over question formulation, study selection, data extraction, data analyses, and interpretation of results. Also, authors are grateful for Dr. Jagpreet Chhatwal and Dr. Jordan King for their willingness to share original data for case studies.

Declaration of interest

JD Chambers has received unrelated research grant funding from Pfizer. JT Cohen has received unrelated research grant funding from Amgen, Biogen, and Janssen Pharmaceutical. Also, the listed author has lectured on the use of simulation modeling for Pfizer. PJ Neumann has received unrelated research grant funding from Janssen Pharmaceutical and has received consulting fees for Vertex Pharmaceutical.

Additional information

Funding

The study was funded by a consortium of funders (Amgen, Biogen, Gilead Sciences, Janssen Pharmaceutical, Novartis, Pfizer, Sanofi US, and Vertex Pharmaceuticals).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 493.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.